Drugs / BiCAR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03941457 | May 2019 → May 2021 | malignant pancreatic neoplasm | Asclepius Technology Company Group (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BiCAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03941457 ↗ |
| Known as | ROBO1 CAR-NK cells | “BiCAR-NK cells (ROBO1 CAR-NK cells)” NCT03941457 ↗ |
| Modality | Cell therapy | “ROBO1 CAR-NK cell immunotherapy” NCT03941457 ↗ |